Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: A systematic review

Gabriele Capurso, Rossella Bettini, Maria Rinzivillo, Letizia Boninsegna, Gianfranco Delle Fave, Massimo Falconi

Research output: Contribution to journalArticle

Abstract

Background: Surgery remains the only curative option for pancreatic neuroendocrine tumours (PNETs), but its indication is limited by metastatic disease in most patients. Indication for removing the primary lesion only in the setting of unresectable liver disease is controversial. The present systematic review aims at determining the potential benefits (survival, progression-free survival) or harms (morbidity, mortality) of surgical resection of the primary lesion only in patients with PNETs and unresectable metastases. Methods: Medline was queried for studies reporting the outcome of PNET patients with unresectable liver metastases whenever there was an explicit comparison between resection of the primary lesion only ('active treatment') and no resection ('non-active treatment'). The primary outcome was survival; possible secondary outcomes were progression-free survival, treatment-related mortality and morbidity, and relief of symptoms. Results: Only 3 cohort studies found were eligible and analysed; no meta-analysis could be performed. The number of patients undergoing 'active treatment' varied from 16 to 20, with a percentage ranging from 17 to 39% of cohorts. Survival was longer in patients who received 'active treatment' in 2 studies, and the 5-year survival rate also seemed higher, without significant complications. Discussion: Available data suggest a possible benefit of resection of the primary lesion only in this setting. However, a bias towards a more aggressive surgical approach in patients with a better performance status or less advanced disease seems likely, and no conclusion can be drawn except for the need of randomised trials. We calculated that such a trial would require at least 118 patients per arm.

Original languageEnglish
Pages (from-to)223-229
Number of pages7
JournalNeuroendocrinology
Volume93
Issue number4
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Neuroendocrine Tumors
Liver Diseases
Disease-Free Survival
Survival
Neoplasm Metastasis
Morbidity
Therapeutics
Mortality
Meta-Analysis
Cohort Studies
Survival Rate
Outcome Assessment (Health Care)
Liver

Keywords

  • Metastatic disease
  • Pancreatic neuroendocrine tumours
  • Surgery
  • Systematic review

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Endocrine and Autonomic Systems
  • Cellular and Molecular Neuroscience

Cite this

Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease : A systematic review. / Capurso, Gabriele; Bettini, Rossella; Rinzivillo, Maria; Boninsegna, Letizia; Fave, Gianfranco Delle; Falconi, Massimo.

In: Neuroendocrinology, Vol. 93, No. 4, 06.2011, p. 223-229.

Research output: Contribution to journalArticle

Capurso, Gabriele ; Bettini, Rossella ; Rinzivillo, Maria ; Boninsegna, Letizia ; Fave, Gianfranco Delle ; Falconi, Massimo. / Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease : A systematic review. In: Neuroendocrinology. 2011 ; Vol. 93, No. 4. pp. 223-229.
@article{29f8d67d36e249fdae6468e0ee446f95,
title = "Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: A systematic review",
abstract = "Background: Surgery remains the only curative option for pancreatic neuroendocrine tumours (PNETs), but its indication is limited by metastatic disease in most patients. Indication for removing the primary lesion only in the setting of unresectable liver disease is controversial. The present systematic review aims at determining the potential benefits (survival, progression-free survival) or harms (morbidity, mortality) of surgical resection of the primary lesion only in patients with PNETs and unresectable metastases. Methods: Medline was queried for studies reporting the outcome of PNET patients with unresectable liver metastases whenever there was an explicit comparison between resection of the primary lesion only ('active treatment') and no resection ('non-active treatment'). The primary outcome was survival; possible secondary outcomes were progression-free survival, treatment-related mortality and morbidity, and relief of symptoms. Results: Only 3 cohort studies found were eligible and analysed; no meta-analysis could be performed. The number of patients undergoing 'active treatment' varied from 16 to 20, with a percentage ranging from 17 to 39{\%} of cohorts. Survival was longer in patients who received 'active treatment' in 2 studies, and the 5-year survival rate also seemed higher, without significant complications. Discussion: Available data suggest a possible benefit of resection of the primary lesion only in this setting. However, a bias towards a more aggressive surgical approach in patients with a better performance status or less advanced disease seems likely, and no conclusion can be drawn except for the need of randomised trials. We calculated that such a trial would require at least 118 patients per arm.",
keywords = "Metastatic disease, Pancreatic neuroendocrine tumours, Surgery, Systematic review",
author = "Gabriele Capurso and Rossella Bettini and Maria Rinzivillo and Letizia Boninsegna and Fave, {Gianfranco Delle} and Massimo Falconi",
year = "2011",
month = "6",
doi = "10.1159/000324770",
language = "English",
volume = "93",
pages = "223--229",
journal = "Neuroendocrinology",
issn = "0028-3835",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease

T2 - A systematic review

AU - Capurso, Gabriele

AU - Bettini, Rossella

AU - Rinzivillo, Maria

AU - Boninsegna, Letizia

AU - Fave, Gianfranco Delle

AU - Falconi, Massimo

PY - 2011/6

Y1 - 2011/6

N2 - Background: Surgery remains the only curative option for pancreatic neuroendocrine tumours (PNETs), but its indication is limited by metastatic disease in most patients. Indication for removing the primary lesion only in the setting of unresectable liver disease is controversial. The present systematic review aims at determining the potential benefits (survival, progression-free survival) or harms (morbidity, mortality) of surgical resection of the primary lesion only in patients with PNETs and unresectable metastases. Methods: Medline was queried for studies reporting the outcome of PNET patients with unresectable liver metastases whenever there was an explicit comparison between resection of the primary lesion only ('active treatment') and no resection ('non-active treatment'). The primary outcome was survival; possible secondary outcomes were progression-free survival, treatment-related mortality and morbidity, and relief of symptoms. Results: Only 3 cohort studies found were eligible and analysed; no meta-analysis could be performed. The number of patients undergoing 'active treatment' varied from 16 to 20, with a percentage ranging from 17 to 39% of cohorts. Survival was longer in patients who received 'active treatment' in 2 studies, and the 5-year survival rate also seemed higher, without significant complications. Discussion: Available data suggest a possible benefit of resection of the primary lesion only in this setting. However, a bias towards a more aggressive surgical approach in patients with a better performance status or less advanced disease seems likely, and no conclusion can be drawn except for the need of randomised trials. We calculated that such a trial would require at least 118 patients per arm.

AB - Background: Surgery remains the only curative option for pancreatic neuroendocrine tumours (PNETs), but its indication is limited by metastatic disease in most patients. Indication for removing the primary lesion only in the setting of unresectable liver disease is controversial. The present systematic review aims at determining the potential benefits (survival, progression-free survival) or harms (morbidity, mortality) of surgical resection of the primary lesion only in patients with PNETs and unresectable metastases. Methods: Medline was queried for studies reporting the outcome of PNET patients with unresectable liver metastases whenever there was an explicit comparison between resection of the primary lesion only ('active treatment') and no resection ('non-active treatment'). The primary outcome was survival; possible secondary outcomes were progression-free survival, treatment-related mortality and morbidity, and relief of symptoms. Results: Only 3 cohort studies found were eligible and analysed; no meta-analysis could be performed. The number of patients undergoing 'active treatment' varied from 16 to 20, with a percentage ranging from 17 to 39% of cohorts. Survival was longer in patients who received 'active treatment' in 2 studies, and the 5-year survival rate also seemed higher, without significant complications. Discussion: Available data suggest a possible benefit of resection of the primary lesion only in this setting. However, a bias towards a more aggressive surgical approach in patients with a better performance status or less advanced disease seems likely, and no conclusion can be drawn except for the need of randomised trials. We calculated that such a trial would require at least 118 patients per arm.

KW - Metastatic disease

KW - Pancreatic neuroendocrine tumours

KW - Surgery

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=79959373617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959373617&partnerID=8YFLogxK

U2 - 10.1159/000324770

DO - 10.1159/000324770

M3 - Article

C2 - 21358176

AN - SCOPUS:79959373617

VL - 93

SP - 223

EP - 229

JO - Neuroendocrinology

JF - Neuroendocrinology

SN - 0028-3835

IS - 4

ER -